Regarding the tumor immune landscape on day 21 post antibody treatment, flow cytometry revealed that the anti-PD-L1 antibody had a synergistic effect with PGRN ablation, resulting in more intratumoral CD8+ T cells as well as CD8+ CTLs (IFN-γ+/GZMB+ CD8+ T cells). The gene discussed is CD8A; the disease is neoplasm.